Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy
Keywords: Fragment-based drug design; Anticancer agents; Drug discovery; STAT3; Breast cancerFBDD, fragment-based drug design; STATs, signal transducers and activators of transcription; ER, estrogen receptor; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluroniu